Outcome of Board meeting held on 01st January 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Kabra Drugs Ltd's board, meeting on 1 January 2026, approved four major strategic decisions. First, the company proposes changing its name to reflect a new business direction, pending MCA and shareholder approval. Second, the board gave in-principle approval to acquire Vassmaan Automotive Pvt Ltd, aiming to enter the Medical Equipment and EV Components manufacturing sector using precision engineering capabilities. Third, the company signed a deal with MR FRANCHISE to onboard 200 channel partners nationwide to boost distribution. Fourth, the board approved amending the Main Objects of the Memorandum of Association to formally include EV Components manufacturing, Steel manufacturing, and Solar Energy equipment and power generation. All items require shareholder approval through an EGM, the date for which will be decided later.
This is a significant business pivot from a pharmaceutical-sounding name into EVs, medical equipment, steel, and solar energy, which could reshape the company's identity and growth story. For shareholders, the acquisition and diversification plans offer new growth avenues but carry execution risk; near-term stock movement will depend on EGM approvals and further details on deal terms.